Select Medical Holdings CORP 8-K filings

Select Medical Holdings Corporation announced the completion of its acquisition by a consortium led by its Executive Chairman, Robert A. Ortenzio, and Welsh, Carson, Anderson & Stowe (WCAS), valuing the company at approximately $3.9 billion.

Select Medical stockholders have voted to approve the company's acquisition by a consortium led by its own executives and WCAS.

Select Medical reported Q1 2026 revenue growth of 5.0% to $1.42 billion while progressing toward a $16.50 per share take-private merger.

Select Medical Holdings Corporation stockholders approved all management proposals at the 2026 Annual Meeting, including a board declassification amendment.

Select Medical Holdings Corporation announced a definitive agreement to be acquired by a consortium led by its executive chairman, co-founder, and WCAS for $16.50 per share in cash, valuing the company at $3.9 billion.

Select Medical Holdings Corporation announced robust financial results for its fourth quarter and full year ended December 31, 2025, alongside a cash dividend declaration and a 2026 business outlook.

Select Medical Holdings Corporation's subsidiary, Select Medical Corporation, has renewed the employment agreement for its Chief Executive Officer, Thomas P. Mullin, effective January 1, 2026.

Select Medical Holdings Corporation acknowledges a non-binding take-private proposal from its Executive Chairman, Robert A. Ortenzio, for $16.00 to $16.20 per share.

Select Medical Holdings Corporation announced a 7.2% revenue increase and a 21.1% rise in EPS for Q3 2025, while also extending its stock repurchase program and raising its full-year EPS guidance.

Select Medical Holdings Corporation announced a series of leadership changes, appointing Thomas P. Mullin as its new Chief Executive Officer, effective September 1, 2025.

Select Medical Holdings Corporation has amended its bylaws to enhance procedural and disclosure requirements for stockholder nominations and proposals, aligning with new SEC universal proxy rules.

Select Medical Holdings Corporation announced robust second-quarter 2025 financial results, including significant increases in net income and earnings per share from continuing operations, while reaffirming its full-year 2025 business outlook.

Select Medical Holdings Corporation announced its first quarter 2025 financial results, including a revenue increase of 2.4% and the declaration of a cash dividend of $0.0625 per share.

Select Medical Holdings Corporation's stockholders approved a new Non-Employee Director Compensation Policy and an amendment to the company's charter at the annual meeting on April 24, 2025.

Select Medical Holdings Corporation reports a revenue increase for Q4 and full year 2024, announces its 2025 business outlook, and declares a cash dividend of $0.0625 per share.

Select Medical Corporation has successfully completed a private offering of $550 million in senior notes due 2032, using the proceeds to refinance existing debt.

Select Medical Holdings Corporation has finalized the spin-off of Concentra through a special stock distribution to its shareholders, valued at approximately $2.3 billion.

Select Medical Corporation has priced a $550 million private offering of senior notes due 2032 to refinance existing debt and redeem outstanding notes.

Select Medical has finalized the distribution ratio for the spin-off of Concentra stock, with shareholders set to receive 0.806971 shares of Concentra for each share of Select Medical held.

Select Medical Holdings Corporation plans to offer $850 million in senior notes to refinance existing debt and amend its credit facilities.

Select Medical Holdings Corporation will distribute its shares of Concentra common stock to its shareholders on November 25, 2024, effectively spinning off Concentra.

Select Medical Holdings Corporation announced a 5.7% increase in revenue and a 33.2% increase in net income for the third quarter of 2024, along with a cash dividend declaration.

Select Medical Holdings Corporation reports the resignation of director Rocco A. Ortenzio and the appointment of CEO David S. Chernow to the board, both effective August 1, 2024.

Select Medical Holdings Corporation announced its second quarter 2024 financial results, including a revenue increase of 5.1%, alongside the declaration of a $0.125 per share cash dividend and the completion of Concentra's IPO.

Select Medical Holdings Corporation completed the separation of its Concentra business through an IPO, using the proceeds to repay debt and establishing new credit facilities for both entities.

Select Medical Holdings Corporation's subsidiary, Concentra Escrow Issuer Corporation, successfully closed a $650 million private offering of senior notes to fund its separation.

Select Medical Holdings Corporation has released estimated financial results for its subsidiary Concentra for the second quarter of 2024, ahead of the company's full earnings announcement.

Concentra Escrow Issuer Corporation has priced a $650 million offering of senior notes due 2032 to finance its separation from Select Medical Holdings Corporation.

Select Medical Holdings Corporation announced a robust first quarter for 2024, marked by significant revenue and profit growth, and declared a cash dividend.

Select Medical Holdings Corporation's shareholders approved amendments to the company's equity incentive plan and charter at the annual meeting on April 25, 2024.